Our Development Pipeline

BPX-04

Topical Minocycline, 1%

BPX-04 (topical minocycline, 1%) is being developed for the treatment of moderate-to-severe papulopustular rosacea. In a Phase 2b study, BPX-04 was shown to be well tolerated and demonstrated efficacy in reducing the number of facial inflammatory lesions among patients. BPX-04 is a topical gel formulation of fully solubilized minocycline.

If you are interested in any of Timber’s ongoing clinical research programs, please contact trials@timberpharma.com.

 Legal Notice | © 2020 by Timber Pharmaceuticals LLC